| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Christoph U Correll, Andreas Brieden, Wolfgang Janetzk. Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-11-07. PMID:37935711. |
we undertook a post hoc analysis of pre-stabilized outpatients with schizophrenia and complete outcome data who had been enrolled in a 6-month non-interventional study of aripiprazole once-monthly (aom) at 75 german sites. |
2023-11-07 |
2023-11-20 |
Not clear |
| Juan J Fernández-Miranda, Silvia Díaz-Fernánde. Plasmatic Levels and Response to Variable Doses of Monthly Aripiprazole and Three-Month Paliperidone in Patients with Severe Schizophrenia. Treatment Adherence, Effectiveness, Tolerability, and Safety. Neuropsychiatric disease and treatment. vol 19. 2023-10-11. PMID:37818449. |
plasmatic levels and response to variable doses of monthly aripiprazole and three-month paliperidone in patients with severe schizophrenia. |
2023-10-11 |
2023-10-15 |
Not clear |
| Jason Poulos, Sharon-Lise T Normand, Katya Zelevinsky, John W Newcomer, Denis Agniel, Haley K Abing, Marcela Horvitz-Lenno. Antipsychotics and the risk of diabetes and death among adults with serious mental illnesses. Psychological medicine. 2023-09-27. PMID:37753625. |
individuals with schizophrenia exposed to second-generation antipsychotics (sga) have an increased risk for diabetes, with aripiprazole purportedly a safer drug. |
2023-09-27 |
2023-10-07 |
Not clear |
| Daniel Schöttle, Klaus Wiedemann, Christoph U Correll, Wolfgang Janetzky, Michael Friede, Holger Jahn, Andreas Briede. Response prediction in treatment of patients with schizophrenia after switching from oral aripiprazole to aripiprazole once-monthly. Schizophrenia research. vol 260. 2023-09-08. PMID:37683508. |
response prediction in treatment of patients with schizophrenia after switching from oral aripiprazole to aripiprazole once-monthly. |
2023-09-08 |
2023-10-07 |
Not clear |
| Leslie Citrome, Pedro Such, Murat Yildirim, Jessica Madera-McDonough, Clodagh Beckham, Zhen Zhang, Frank Larsen, Matthew Harli. Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients With Schizophrenia in a Randomized, Open-label, Parallel-Arm, Pivotal Study. The Journal of clinical psychiatry. vol 84. issue 5. 2023-09-06. PMID:37672016. |
safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with schizophrenia in a randomized, open-label, parallel-arm, pivotal study. |
2023-09-06 |
2023-10-07 |
Not clear |
| Magdalena Górny, Anna Bilska-Wilkosz, Małgorzata Iciek, Zofia Rogóż, Elżbieta Lorenc-Koc. Treatment with aripiprazole and N-acetylcysteine affects anaerobic cysteine metabolism in the hippocampus and reverses schizophrenia-like behavior in the neurodevelopmental rat model of schizophrenia. The FEBS journal. 2023-08-30. PMID:37646112. |
treatment with aripiprazole and n-acetylcysteine affects anaerobic cysteine metabolism in the hippocampus and reverses schizophrenia-like behavior in the neurodevelopmental rat model of schizophrenia. |
2023-08-30 |
2023-09-07 |
rat |
| Vanessa Sanchez-Gistau, María José Moreno, Susana Gómez-Lus, Antoni Sicras-Mainar, Benedicto Crespo-Facorr. Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study. Frontiers in psychiatry. vol 14. 2023-08-21. PMID:37599866. |
healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: ambition, a real-world study. |
2023-08-21 |
2023-09-07 |
Not clear |
| Vanessa Sanchez-Gistau, María José Moreno, Susana Gómez-Lus, Antoni Sicras-Mainar, Benedicto Crespo-Facorr. Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study. Frontiers in psychiatry. vol 14. 2023-08-21. PMID:37599866. |
this study aims to compare the hospitalization rate in individuals with schizophrenia who started their treatment with aripiprazole once monthly (aom400) or atypical oral antipsychotics (oa) in spain. |
2023-08-21 |
2023-09-07 |
Not clear |
| Cailian Lu, Shan Li, Lin Kang, Qianqian Li, Hongxu Chen, Yanwen Lin, Han Zhang, Ziling Tang, Meiyan Bai, Peng Xion. Aripiprazole combined with nerve growth factor improves cognitive function in mice with schizophrenia model. Neuroscience letters. 2023-07-26. PMID:37495071. |
aripiprazole combined with nerve growth factor improves cognitive function in mice with schizophrenia model. |
2023-07-26 |
2023-08-14 |
mouse |
| Xueping Wang, Dongli Mei, Zhe Lu, Yuyanan Zhang, Yaoyao Sun, Tianlan Lu, Hao Yan, Weihua Yu. Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-07-25. PMID:37491364. |
genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. |
2023-07-25 |
2023-08-14 |
Not clear |
| Xueping Wang, Dongli Mei, Zhe Lu, Yuyanan Zhang, Yaoyao Sun, Tianlan Lu, Hao Yan, Weihua Yu. Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-07-25. PMID:37491364. |
aripiprazole is recommended for routine use in schizophrenia patients. |
2023-07-25 |
2023-08-14 |
Not clear |
| Xueping Wang, Dongli Mei, Zhe Lu, Yuyanan Zhang, Yaoyao Sun, Tianlan Lu, Hao Yan, Weihua Yu. Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-07-25. PMID:37491364. |
however, the biological mechanism for the adverse drug reactions (adrs) among schizophrenia patients with the antipsychotic drug aripiprazole is far from clear. |
2023-07-25 |
2023-08-14 |
Not clear |
| Xueping Wang, Dongli Mei, Zhe Lu, Yuyanan Zhang, Yaoyao Sun, Tianlan Lu, Hao Yan, Weihua Yu. Genome-wide association study identified six loci associated with adverse drug reactions to aripiprazole in schizophrenia patients. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-07-25. PMID:37491364. |
to explore the potential genetic factors that may cause movement-related adverse antipsychotic effects in patients, we conducted an association analysis between movement-related adrs and snps in schizophrenia patients receiving aripiprazole monotherapy. |
2023-07-25 |
2023-08-14 |
Not clear |
| Gabriel D Flores-Gómez, David Javier Apam-Castillejos, Ismael Juárez-Díaz, Estefania Fuentes-Medel, Alfonso Díaz, Hiram Tendilla-Beltrán, Gonzalo Flore. Aripiprazole attenuates the medial prefrontal cortex morphological and biochemical alterations in rats with neonatal ventral hippocampus lesion. Journal of chemical neuroanatomy. 2023-07-22. PMID:37481172. |
in this study, it was evaluated the effect of the atypical antipsychotic aripiprazole (ari) on the behavioral and mpfc neuronal disturbances of rats with neonatal ventral hippocampus lesion (nvhl), which is a heuristic developmental model relevant to the study of schizophrenia. |
2023-07-22 |
2023-08-14 |
rat |
| Pierre Baumann, Philipp Bauknecht, Maxim Kuzin, Georgios Schoretsaniti. Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review. International journal of psychiatry in clinical practice. 2023-07-10. PMID:37428441. |
the aim of this review is to analyse the literature regarding studies centred on the clinical outcome of individuals affected by schizophrenia and treated with various antipsychotics, and then switched to orally administered partial d2-dopamine agonists (pd2a): aripiprazole (ari), brexpiprazole (brex) or cariprazine (cari). |
2023-07-10 |
2023-08-14 |
Not clear |
| Fumiaki Yamasaki, Nobuhisa Kanahara, Yusuke Nakata, Shinji Koyoshi, Yuta Yanagisawa, Takeru Saito, Takahiro Oiwa, Masanobu Kogure, Tsuyoshi Sasaki, Taisuke Yoshida, Hiroshi Kimura, Masaomi Iy. Can brexpiprazole be switched safely in patients with schizophrenia and dopamine supersensitivity psychosis? A retrospective analysis in a real-world clinical practice. Journal of psychopharmacology (Oxford, England). 2023-07-03. PMID:37395368. |
several studies have reported that a switch to the dopamine partial agonist (dpa) aripiprazole (arp), especially when the switch is abrupt, is likely to fail and sometimes worsen psychosis in schizophrenia patients already under high-dose antipsychotic treatment. |
2023-07-03 |
2023-08-14 |
Not clear |
| Manoj Kumar Sahoo, Harshita Biswas, Sandeep Grove. Safety Profile of Aripiprazole During Pregnancy and Lactation: Report of 2 Cases. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 34. issue 2. 2023-06-26. PMID:37357900. |
aripiprazole, a second-generation antipsychotic (sga) medication, is an efficacious treatment for schizophrenia and bipolar disorder. |
2023-06-26 |
2023-08-14 |
Not clear |
| Matthew Harlin, Craig Chepke, Frank Larsen, Karimah S Bell Lynum, Sanjeda R Chumki, Heather Fitzgerald, Pedro Such, Jessica Madera-McDonough, Murat Yildirim, Moeen Panni, Stephen R Sakla. Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison. Neuropsychiatric disease and treatment. vol 19. 2023-06-14. PMID:37313228. |
aripiprazole 2-month ready-to-use 960 mg (ari 2mrtu 960) is a novel long-acting injectable (lai) formulation of aripiprazole monohydrate for administration once every 2 months, developed for the treatment of schizophrenia or maintenance monotherapy treatment of bipolar i disorder in adults (indication will vary by country). |
2023-06-14 |
2023-08-14 |
Not clear |
| Matthew Harlin, Craig Chepke, Frank Larsen, Karimah S Bell Lynum, Sanjeda R Chumki, Heather Fitzgerald, Pedro Such, Jessica Madera-McDonough, Murat Yildirim, Moeen Panni, Stephen R Sakla. Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison. Neuropsychiatric disease and treatment. vol 19. 2023-06-14. PMID:37313228. |
aripiprazole lauroxil 1064 mg (al 1064) is an lai formulation of aripiprazole lauroxil, an aripiprazole prodrug, for administration once every 2 months, indicated for the treatment of schizophrenia in adults. |
2023-06-14 |
2023-08-14 |
Not clear |
| Oloruntoba Oluboka, Guerline Clerzius, Wolfgang Janetzky, Daniel Schöttle, François Therrien, Klaus Wiedemann, Marc-André Ro. Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study). BMC psychiatry. vol 23. issue 1. 2023-05-31. PMID:37259053. |
improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (react study). |
2023-05-31 |
2023-08-14 |
Not clear |